Our analyses reveal that germline mutations F1662S and M1663K disrupt the ability of BRCT to dimerize, in vitro and in vivo, providing a structural explanation for the possible role of these mutations in inactivating BRCA1 tumor suppressor function. This evidence concerns the gene BRCA1 and neoplasm.